Four out of every five prescriptions Americans fill now covered
In a nation where the cost of medicine has long divided those who can afford care from those who cannot, the Trump administration has expanded its TrumpRx.gov discount program to cover more than 800 prescription medications — roughly four out of five prescriptions filled by Americans. Struck through agreements with 16 major pharmaceutical companies, the deals exchange tariff relief for lower prices, extending discounts to uninsured and cash-paying patients. The move represents a deliberate attempt to rewrite the terms of a long-standing imbalance, one in which Americans have paid more than patients in other wealthy nations for the same drugs.
- The program has grown from 640 to over 800 medications in a matter of weeks, signaling an accelerating push to reshape how Americans pay for prescriptions.
- Tariffs are being wielded as a negotiating weapon — pharmaceutical giants like Eli Lilly and Novo Nordisk accepted price cuts rather than face trade penalties, a pressure tactic that upends the usual dynamic between government and industry.
- The administration's claimed savings figures — including reductions described as 400 to 600 percent — have drawn scrutiny, with critics noting the language appears to conflate markup ratios with actual consumer savings.
- For uninsured and cash-paying patients, the website offers a practical workaround to the insurance system, letting users search medications, compare savings, and print pharmacy coupons directly.
- With $400 million in claimed savings and explicit plans for further expansion, the administration is signaling that prescription drug pricing will remain a defining policy battleground through the rest of 2026.
President Trump announced Friday that TrumpRx.gov, his administration's prescription drug discount platform, has expanded to cover more than 800 medications — up from roughly 640 just weeks prior. The site allows Americans, particularly those without insurance, to search for discounted drugs and generate pharmacy coupons without navigating the traditional insurance system. By the administration's count, the program now touches roughly four out of every five prescriptions filled in the United States.
The expansion was made possible through agreements with 16 major pharmaceutical companies, who accepted lower prices in exchange for exemptions from pharmaceutical tariffs. Eli Lilly and Novo Nordisk are among the participants, having agreed to reduce costs on GLP-1 weight-loss drugs — medications that have become a flashpoint in the broader debate over prescription affordability. The program also covers inhalers, HIV treatments, diabetes medications, and fertility drugs.
Trump first introduced the concept of most-favored-nation pricing in February, arguing that Americans have historically paid far more than patients in other developed countries for identical medications. He has framed tariffs as the leverage that forced companies to the table — a reversal, in his telling, of decades of policy that favored pharmaceutical profits over patients. The administration claims the program has already delivered over $400 million in savings, though some of the figures cited in Trump's announcement appear to conflate markup percentages with actual price reductions.
With explicit plans to pursue additional most-favored-nation agreements, the administration is treating drug pricing as a central priority for the remainder of 2026. Whether the savings claims will withstand independent scrutiny, and whether the program can sustain its rapid growth, are questions that remain open — but the scale and pace of the expansion leave little doubt about the political weight the White House is placing on this initiative.
On Friday, President Trump announced that his administration's prescription drug discount program has grown to cover more than 800 medications, up from roughly 640 just weeks earlier. The expansion adds 160 new drugs to TrumpRx.gov, a government-backed website designed to let Americans search for and access discounted prescriptions without insurance. According to Trump's statement, the program now covers roughly four out of every five prescriptions that Americans fill.
The initiative rests on a series of agreements the administration negotiated with 16 major pharmaceutical companies. In exchange for tariff exemptions, these companies agreed to offer lower prices on certain medications and to extend those discounts to uninsured or cash-paying customers through the TrumpRx platform. Among the participating companies are Eli Lilly and Novo Nordisk, both of which have agreed to reduce prices on GLP-1 weight-loss medications—drugs that have become central to conversations about prescription affordability in recent years. The program also covers inhalers, HIV treatments, diabetes medications, and fertility drugs.
Trump first introduced the concept of "most-favored-nation" pricing in February, arguing that Americans have long paid substantially more for the same medications than patients in other developed countries. The idea is straightforward: if a drug costs less in Canada or Germany, Americans should pay no more than that price. In his announcement, Trump claimed the pricing cuts sometimes reach 400, 500, or even 600 percent reductions—language that appears to conflate the discount percentage with the original price markup rather than the final savings amount. The administration says the program has already saved patients over $400 million since launch.
The website itself functions as a straightforward tool. Users can search for specific medications, see how much they might save, and generate coupons to bring to pharmacies. This approach sidesteps the traditional insurance system for those who need it, creating a parallel track for price-conscious consumers.
Trump has positioned tariffs as the key lever that made these negotiations possible. He argues that the threat of tariffs on imported pharmaceuticals gave the administration real bargaining power—forcing companies to choose between accepting lower prices and facing trade penalties. He framed this as a reversal of decades of policy that, in his view, allowed pharmaceutical companies to charge Americans inflated prices while other countries paid far less for identical drugs.
The expansion signals the administration's intent to pursue more such agreements. Trump said he has instructed his team to secure additional most-favored-nation deals and partnerships aimed at lowering prices across the pharmaceutical market. Whether the program can sustain this expansion, and whether the claimed savings figures hold up under scrutiny, remains to be seen. But the scale of the announcement—800 medications, $400 million in claimed savings, and explicit plans for further growth—suggests the administration views prescription drug pricing as a central policy priority heading into the second half of 2026.
Notable Quotes
TrumpRx.gov will now provide clear, transparent, and discounted offerings for four out of five of every prescription filled by Americans— President Trump
Most-favored-nation pricing would not be possible without tariffs, which force other countries to pay their fair share instead of relying on American patients to subsidize global drug prices— President Trump (paraphrased)
The Hearth Conversation Another angle on the story
How does most-favored-nation pricing actually work in practice? Is it just a coupon system?
It's more than that. The government negotiated directly with drug companies, saying: match your lowest international price or face tariffs. Then TrumpRx.gov became the distribution mechanism—a way for uninsured Americans to access those negotiated prices without going through insurance middlemen.
So the tariff threat is what made companies agree?
That's the administration's claim, yes. The companies got tariff exemptions in return for accepting lower prices. It's leverage, essentially—trade policy weaponized for drug pricing.
Four out of five prescriptions seems like a huge number. How did they get there so fast?
They added 160 drugs in this expansion alone. The program started with around 640 medications, so they're moving quickly. But "four out of five" is their calculation of market coverage—it's about which drugs Americans actually fill, not total drug variety.
What about the $400 million in savings? That sounds enormous.
It's what they're claiming. But that's aggregate savings across millions of prescriptions over several months. The real question is whether those savings stick, and whether they're real discounts or accounting adjustments.
Why would Eli Lilly and Novo Nordisk agree to this?
GLP-1 drugs are hugely profitable and in massive demand. The companies probably calculated that some discount is better than facing tariffs or losing market share to competitors. Plus, the publicity around "affordable weight-loss drugs" isn't bad for their brand.
What happens next?
The administration says it's pursuing more deals. The real test is whether other companies join, whether the discounts hold, and whether this actually changes how Americans experience drug costs at the pharmacy counter.